BioSpace News Archive

Quantabio today announced the commercial availability of the sparQ RNA-Seq HMR Kit , an ultra-fast RNA next-generation sequencing (NGS).

Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eugene Zhukovsky, Ph.D., to the position of Chief Scientific Officer (CSO), effective immediately.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, before the open of the financial markets on Tuesday, March 8, 2022.

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that the Company will present at the Oppenheimer 32nd Annual Healthcare Conference.

Yield10 Bioscience, Inc. today announced that 2021 field test results show that the trait C3020 tested in Camelina and C3007 tested in canola produce increases in seed oil content.

Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO along with members of management, will conduct a virtual fireside chat at the Cowen 42nd Annual Healthcare Conference.

ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), and ZeeDimension, a technology and quality consulting company based in Dubai, UAE, have partnered to deliver unique digital validation solutions for pharmaceutical companies in the Middle East.

Today Vyant Bio released a Letter to Shareholders from Chief Executive Officer, Jay Roberts.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.